Gilead (GILD) to Launch Generics for Leading HCV Treatments

Gilead Sciences Inc GILD announced that it plans to launch authorized generic versions of its leading hepatitis C virus HCV treatments Epclusa sofosbuvir 400mg velpatasvir 100mg and Harvoni ledipasvir 90mg sofosbuvir 400mg The generic versions will be launched through a newly

Source

The post Gilead (GILD) to Launch Generics for Leading HCV Treatments appeared first on Cannabis Stock Picks.

Go to OG News Source
Author: Admin
{authorlink}